Algorae Pharmaceuticals Limited
LVCLF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | 198% | 1,134% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 100% | 98.7% | 78.2% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $1 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $1 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $1 | $0 |
| Operating Expenses | $2 | $2 | $2 | $2 |
| Operating Income | -$2 | -$2 | -$2 | -$2 |
| % Margin | – | -1,659.5% | -4,968.3% | -70,042.7% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$2 | -$2 | -$2 | -$2 |
| Tax Expense | $1 | $0 | $0 | -$0 |
| Net Income | -$1 | -$2 | -$2 | -$2 |
| % Margin | – | -1,673.8% | -5,016.3% | -57,483.1% |
| EPS | -0.001 | -0.001 | -0.002 | -0.002 |
| % Growth | 61.5% | 18.8% | 27.3% | – |
| EPS Diluted | -0.001 | -0.001 | -0.002 | -0.002 |
| Weighted Avg Shares Out | 1,609 | 1,613 | 1,347 | 887 |
| Weighted Avg Shares Out Dil | 1,687 | 1,663 | 1,347 | 887 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $0 | $0 | $0 |
| EBITDA | $0 | -$2 | -$2 | -$1 |
| % Margin | – | -1,261.3% | -3,619.7% | -42,848.3% |